During these neurological disorders, there is an overexpression of KV1.3 channels concluding that KV1.3 specific blockers could mitigate neuroinflammation, and become specific therapeutic candidates during AD or PD (reviewed in Revuelta et al., 2022). This evidence concerns the gene KCNA3 and Parkinson disease.